NEW YORK – Blueprint Medicines earlier this week announced that it will submit a supplemental new drug application with the US Food and Drug Administration for avapritinib (Ayvakit) in patients with advanced systemic mastocytosis (SM), a disorder that results from too many mast cells in the body and can turn into cancer.